Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03288766 · ClinicalTrials.gov registry record
SHERLOCK 3CG™ Diamond Tip Confirmation System
A clinical trial, sponsored by C. R. Bard.
- Terminated
- Registry status
- 232
- Enrollment target
NCT03288766: Clinical Trial study, sponsored by C. R. Bard.
NCT03288766 is a clinical trial that was terminated before completion, run by C. R. Bard. The registered enrollment target is 232 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03288766 was terminated before completion, sponsored by C. R. Bard.
- TERMINATED
- Registry status
- 232 participants
- Enrollment target
Study Summary
This study is a single-arm, prospective, multi-center study to assess clinical performance of the SHERLOCK 3CG™ Diamond Tip Confirmation System (TCS) with MODUS II software for confirming correct tip position of peripherally inserted central catheters (PICCs) in adult subjects with altered cardiac rhythm.
Primary Outcome
Tip positioning is determined at bedside by the software via the Green Diamond Indicator (GDI+) and confirmed by CXR. PICC tip placement will be considered successful if it is determined to be in the lower 1/3 of the SVC or in the CAJ by an independent, blinded radiologist judging position retrospectively against pre-specified anatomical criteria.
Interventions
- PROCEDURE PICC placement with SHERLOCK 3CG™ Diamond TCS with MODUS II software
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 232 participants |
| Start Date | 2018-04-19 |
| Est. Completion | 2021-06-15 |
Why NCT03288766 stopped before completion
NCT03288766 is an observational study that tracks outcomes without assigning an intervention. The registered 232 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 1 intervention - of which PICC placement with SHERLOCK 3CG™ Diamond TCS with MODUS II software is the first listed.
NCT03288766 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03288766 about?
NCT03288766 is a clinical study titled "SHERLOCK 3CG™ Diamond Tip Confirmation System". This study is a single-arm, prospective, multi-center study to assess clinical performance of the SHERLOCK 3CG™ Diamond Tip Confirmation System (TCS) with MODUS II software for confirming correct tip position of peripherally inserted central catheters (PICCs) in adult subjects with altered cardiac r...
What is the current status of trial NCT03288766?
This trial is currently terminated. The enrollment target is 232 participants. The study started on 2018-04-19. Estimated completion is 2021-06-15.
What interventions are being tested in trial NCT03288766?
The interventions under investigation include: PICC placement with SHERLOCK 3CG™ Diamond TCS with MODUS II software (PROCEDURE).
Who is sponsoring clinical trial NCT03288766?
This trial is sponsored by C. R. Bard, which has 75 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01356290 · 232 participants · Phase 2
Antiangiogenic Therapy for Children With Recurrent Medulloblastoma, Ependymoma, ATRT and Rare CNS Tumors
- NCT04753359 · 232 participants · NA
Mediterranean Diet and Weight Loss: Targeting the Bile Acid/Gut Microbiome Axis to Reduce Colorectal Cancer
- NCT04770870 · 232 participants · NA
Post Approval Study2: Hintermann Series H3 Total Ankle Replacement System
- NCT05948943 · 232 participants · Phase 2
Alpelisib in Pediatric and Adult Patients With Lymphatic Malformations Associated With a PIK3CA Mutation.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI